Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$49.82

-5.615 (-10.13%)

, MRK

Merck

$63.85

1.075 (1.71%)

15:09
10/10/16
10/10
15:09
10/10/16
15:09

Opdivo trial results may hang on Bristol-Myers shares, WSJ says

Bristol-Myers Squibb's (BMY) disappointing Opdivo trial results may continue to weigh on the shares, Charley Grant writes in the Wall Street Journal's Heard on the Street column. Grant noted that Merck (MRK) presented strong lung cancer data with its Keytruda treatment at the same meeting as Bristol-Myers and may be able to fetch outsized gains. Though Opdivo has outsold Keytruda so far, Bristol-Myers will have a difficult time meeting its growth targets if the lung cancer market slips away, the column says. Reference Link

BMY

Bristol-Myers

$49.82

-5.615 (-10.13%)

MRK

Merck

$63.85

1.075 (1.71%)

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

BMY Bristol-Myers
$49.82

-5.615 (-10.13%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
MRK Merck
$63.85

1.075 (1.71%)

10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

MSTX

Mast Therapeutics

$0.14

0.003 (2.22%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Mast Therapeutics to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

MTSI

MACOM

$50.32

-3.52 (-6.54%)

, SBGI

Sinclair Broadcast

$40.35

1.05 (2.67%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
National Association of Broadcasters to hold a conference »

NAB Show 2017 is being…

MTSI

MACOM

$50.32

-3.52 (-6.54%)

SBGI

Sinclair Broadcast

$40.35

1.05 (2.67%)

NXST

Nexstar

$69.90

1 (1.45%)

TRCO

Tribune Media

$36.72

0.17 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 09

    May

  • 22

    May

  • 23

    May

CLLS

Cellectis

$23.83

0.26 (1.10%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Cellectis management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 03

    May

  • 06

    Jun

RDHL

RedHill Biopharma

$10.29

0.0199 (0.19%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
RedHill Biopharma to host research and development day »

Research &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 03

    May

RXDX

Ignyta

$9.20

0.25 (2.79%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Ignyta holds a conference call »

Management provides a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 06

    Jun

BGG

Briggs & Stratton

$25.14

0.09 (0.36%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Briggs & Stratton management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 10

    May

GTN

Gray Television

$15.05

0.4 (2.73%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Gray Television management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 03

    May

  • 04

    May

SGM

Stonegate Mortgage

$7.96

-0.0059 (-0.07%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Stonegate Mortgage to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/21 EIA Natural…

CMRX

Chimerix

$6.09

-0.01 (-0.16%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Chimerix to hold an investor update webcast »

Chief Medical Officer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Pending Home Sales Index to be reported at 10:00 »

March Pending Home Sales…

RGLS

Regulus

$1.55

0.1 (6.90%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Regulus management to meet with Needham »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Berenberg to hold a conference »

U.K. Corporate Conference…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
The Food & Drug Law Institute to hold a conference »

Introduction to U.S. Drug…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 4/22 Jobless…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/23 Bloomberg…

LGF

Use LGF.A, LGF.B

, AMCX

AMC Networks

$60.25

0.65 (1.09%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
FBN Securities media/cable analyst holds an analyst/industry conference call »

Media. Cable &…

LGF

Use LGF.A, LGF.B

AMCX

AMC Networks

$60.25

0.65 (1.09%)

DISCA

Discovery

$29.39

0.1 (0.34%)

CBS

CBS

$66.91

0.5 (0.75%)

NFLX

Netflix

$150.17

-1.99 (-1.31%)

AMZN

Amazon.com

$909.29

1.67 (0.18%)

VIA.B

Symbol now VIAB

NLSN

Nielsen

$39.41

-0.57 (-1.43%)

SNI

Scripps Networks

$76.49

0.53 (0.70%)

TWX

Time Warner

$100.20

0.16 (0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 16

    May

  • 16

    May

  • 18

    May

  • 18

    May

  • 23

    May

  • 31

    May

  • 05

    Jun

  • 15

    Jun

MEOH

Methanex

$46.10

0.15 (0.33%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Methanex Corporation to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Durable Goods Orders Ex-transportation to be reported at 08:30 »

March Durable Goods…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Durable Goods Orders to be reported at 08:30 »

March Durable Goods…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/26 Fed Balance…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

Week of 4/17 Money Supply…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

04:55
04/27/17
04/27
04:55
04/27/17
04:55
General news
Breaking General news story  »

3-Month Bill Announcement…

WWD

Woodward

$68.05

-0.11 (-0.16%)

04:55
04/27/17
04/27
04:55
04/27/17
04:55
Conference/Events
Woodward management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 28

    Apr

  • 09

    May

  • 11

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.